EMA Withdrawn: Ulipristal Acetate Gedeon Richter (ulipristal acetate) — Gedeon Richter Plc.

View source ↗

Summary

EMA withdrawal of Ulipristal Acetate from Gedeon Richter for leiomyoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyoma

Drugs mentioned

• Ulipristal Acetate (Gedeon Richter) (ulipristal acetate)

Snippet

Status: Withdrawn. Therapeutic area: Leiomyoma. MAH: Gedeon Richter Plc.. Decision date: 14/06/2021